2023
Advances in understanding and treating diabetic kidney disease: focus on tubulointerstitial inflammation mechanisms
Xu C, Ha X, Yang S, Tian X, Jiang H. Advances in understanding and treating diabetic kidney disease: focus on tubulointerstitial inflammation mechanisms. Frontiers In Endocrinology 2023, 14: 1232790. PMID: 37859992, PMCID: PMC10583558, DOI: 10.3389/fendo.2023.1232790.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDiabetic kidney diseaseTubulointerstitial lesionsKidney diseaseInflammation mechanismsManagement of DKDEnd-stage kidney diseaseMineralocorticoid receptor antagonistsImmune-inflammatory mechanismsPro-inflammatory cytokinesAldosterone blockadeDKD outcomesInflammatory mechanismsSerious complicationsKidney functionGlomerular lesionsReceptor antagonistClinical trialsKidney volumeT cellsPreclinical studiesTubulointerstitial regionsLesionsTherapyDiseaseRecent studies
2021
Effect of Mahuang Fuzi and Shenzhuo Decoction on Idiopathic Membranous Nephropathy: A Multicenter, Nonrandomized, Single-Arm Clinical Trial
Dong Z, Dai H, Gao Y, Jiang H, Liu M, Liu F, Liu W, Feng Z, Zhang X, Ren A, Li X, Rui H, Tian X, Li G, Liu B. Effect of Mahuang Fuzi and Shenzhuo Decoction on Idiopathic Membranous Nephropathy: A Multicenter, Nonrandomized, Single-Arm Clinical Trial. Frontiers In Pharmacology 2021, 12: 724744. PMID: 34733157, PMCID: PMC8558382, DOI: 10.3389/fphar.2021.724744.Peer-Reviewed Original ResearchIdiopathic membranous nephropathySingle-arm clinical trialMahuang-FuziMembranous nephropathyCourse of treatmentRemission rateImmunosuppressive therapyDisease remissionUrine proteinClinical trialsSevere adverse eventsCases of patientsMean followAdverse eventsRenal functionClinical effectsNephropathyPatientsBlood albuminRemissionTherapyDecoctionMulticenterObjective performance criteriaTreatment
2016
Targeting the podocyte cytoskeleton: from pathogenesis to therapy in proteinuric kidney disease
Tian X, Ishibe S. Targeting the podocyte cytoskeleton: from pathogenesis to therapy in proteinuric kidney disease. Nephrology Dialysis Transplantation 2016, 31: 1577-1583. PMID: 26968197, PMCID: PMC5039341, DOI: 10.1093/ndt/gfw021.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsProteinuric kidney diseaseKidney diseaseGlomerular filtration barrierChronic kidney diseaseLack of therapyFiltration barrierIntact glomerular filtration barrierMillions of patientsImportance of podocytesHuman nephrotic syndromeGlomerular injuryNephrotic syndromeTherapeutic implicationsTherapeutic targetPodocyte actin cytoskeletonDisease pathogenesisExciting new dataPathogenesisEpithelial cellsGenetic mutationsDiseasePodocyte cytoskeletonTherapyProgressionPodocytes